DMDenise E. Morris

Denise E. Morris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denise E. Morris has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • David W. Cleary

    Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK

    6 shared publications
  • Stuart Charles Clarke

    University of Southampton University Hospital Southampton NHS Trust Universiti Tunku Abdul Rahman Universiti Sultan Zainal Abidin

    6 shared publications
  • Alex J. J. Lister

    University of Southampton, Tremona Road, Southampton, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK

    3 shared publications
  • Ahmed Ghazi Alattraqchi

    Centre for Research in Infectious Diseases and Biotechnology, Faculty of Medicine Universiti Sultan Zainal Abidin Kuala Terengganu Malaysia

    2 shared publications
  • Chew Chieng Yeo

    Centre for Research in Infectious Diseases and Biotechnology (CeRIDB), Faculty of Medicine, Universiti Sultan Zainal Abidin, Kuala Terengganu, Malaysia

    2 shared publications
  • Rebecca Anderson

    Faculty of Medicine and Institute for Life Sciences University of Southampton Southampton UK

    2 shared publications

Latest Publications

  • Open Access

    DrugSet: A validated R Shiny application for reproducible drug codelist construction from ATC classification to CPRD Aurum prodcodes

    by Vjola Hoxhaj, Catherine Fry, Denise E Morris, Taylor Aurelius, Samantha Lane, Miriam Sturkenboom, Constanza L. Andaur Navarro

    KEY POINTS: Constructing semantically harmonized drug codelists for pharmacoepidemiologic research across data sources is often manual, time-consuming, and prone to inconsistencies as many datasources but not all (e.g. CPRD Aurum) use the ATC coding system. DrugSet is a validated open-source R Shiny application that integrates ATC-based hierarchical code selection, string-based matching on pre-specified variables mapping to CPRD Aurum prodcodes, and codelist export within a single workflow operating directly on native vocabulary files. DrugSet demonstrated high accuracy for both ATC codelist generation and prodcodes mapping, and reduced the time required for codelist construction compared to manual approaches. PLAIN LANGUAGE SUMMARY: Health research focused on use and safety of medicines depends on accurate lists of drug codes, called codelists, to identify which medicines the patients received. Building these lists is currently a manual process, which makes it slow, error-prone, and difficult to reproduce across studies. We developed DrugSet, an open-source tool that helps researchers build drug codelists in a structured and consistent way. The tool uses the international drug classification system (ATC: Anatomical Therapeutic Chemical) to identify drug groups of interest and automatically links these to the specific codes used in the largest United Kingdom primary care data source (CPRD: Clinical Practice Research Datalink Aurum). By leveraging the route-of-administration information already embedded in the ATC hierarchy, it also distinguishes, for example, topical from systemic formulations. We tested DrugSet on three drug types, metformin, beta-blockers, and topical salicylic acid and found that it produced results matching reference standards, completing the task in minutes rather than hours. DrugSet is freely available to support transparent, reproducible for pharmacoepidemiological research. Objectives: To present DrugSet, a validated R Shiny application supporting the construction medicinal products codelists based on the Anatomical Therapeutic Chemical (ATC) system and their mapping to Clinical Practice Research Datalink (CPRD) Aurum prodcodes within a single interactive workflow. Materials and Methods: DrugSet comprises four modules: data preparation, ATC-based hierarchical code selection, string-based CPRD Aurum prodcodes mapping, and codelist export. Validation was conducted against World Health Organization (WHO) ATC reference codelists and manually curated prodcodes mappings across three drug classes: metformin, beta-blocking agents, and topical salicylic acid. Sensitivity, specificity, and Positive Predictive Values (PPV) were calculated for ATC codelist generation. Agreement proportions (overlapping against total identified codes) were calculated for prodcodes mapping. Time needed for codelist construction using DrugSet was recorded and compared to manual approaches. Results: DrugSet’s ATC codelist generation against WHO manual reference achieved 100% sensitivity, specificity, and PPV across all medicinal products. Prodcodes mapping agreement ranged from 89.2% to 98.3% with discrepancies due to missing data in the prodcodes input vocabulary. DrugSet completed codelist construction in 9 minutes compared to 3 hours and 10 minutes manually, across all medicinal products classes. Discussion: DrugSet provides a unified workflow that runs directly on ATC and source CPRD Aurum vocabulary files. The reduction in codelist construction time and export of the generated codelists supports reproducibility in pharmacoepidemiologic studies where codelist creation can represent a significant proportion of study setup time. Conclusion: DrugSet is an open-source, validated tool that improves accuracy, and efficiency of codelist construction for medicinal products based on ATC codes towards CPRD Aurum prodcodes.

  • Open Access

    Carriage epidemiology of Moraxella catarrhalis in an all-age community cohort between 2016 and 2018

    by Denise E. Morris, Alex J. J. Lister, David W. Cleary, Stuart C. Clarke

    Moraxella catarrhalis is an increasingly important pathogen, recognized as a common cause of respiratory tract infections. It is particularly known for its role in causing otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults. With growing interest in developing vaccines against M. catarrhalis , a deeper understanding of epidemiology in both carriage and disease is crucial. Here, we present an all-age, community-based, upper respiratory tract carriage study (the Solent SMART Study) designed to investigate the epidemiology of, and risk factors for, M. catarrhalis carriage. In total, n =1,622 community-based participants were recruited with an additional n =79 individuals recruited from care/nursing homes in the Southampton/Hampshire UK region from whom a total of n =228 M . catarrhalis were isolated. Carriage prevalence was 8% (95% CI: 6.7–9.4%) in community-based participants, 19% (95% CI: 11.0–29.4%) in care/nursing home residents and 4.7% (95% CI: 1.6–10.7%) in the community-based subset with COPD ( n =106). Nasopharyngeal carriage site, young age, microbial co-carriage with Streptococcus pneumoniae , Haemophilus influenzae and Neisseria meningitidis and recent/concurrent respiratory tract infection were all positively associated with the carriage of M. catarrhalis . Antimicrobial resistance testing showed that n =91 (41.4%) of the 220 isolates tested resistant to at least 1 antibiotic, with the most frequent being resistance to chloramphenicol ( n =76, 34.5%) and ciprofloxacin ( n =64, 29.1%).

  • Open Access

    Carriage epidemiology of Moraxella catarrhalis in an all-age, community cohort between 2016 - 2018

    by Denise E. Morris, Alex J. J. Lister, David W. Cleary, Stuart C. Clarke

    Moraxella catarrhalis is an increasingly important pathogen, recognised as a common cause of respiratory tract infections. It is particularly known for its role in causing otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults. With growing interest in developing vaccines against M. catarrhalis, a deeper understanding of epidemiology in both carriage and disease is crucial. Here we present an all-age, community-based, upper respiratory tract carriage study (the Solent SMART Study) designed to investigate the epidemiology of, and risk factors for M. catarrhalis carriage. In total, n = 1,622 community-based participants were recruited with an additional n = 79 individuals recruited from care/nursing homes in the Southampton/Hampshire UK region from whom a total of n = 228 M. catarrhalis were isolated. Carriage prevalence was 8% (95% CI: 6.7-9.4%) in community-based participants, 19% (95% CI: 11.0-29.4%) in care/nursing home residents and 4.7% (95% CI: 1.6-10.7%) in the community-based subset with COPD (n = 106). Nasopharyngeal carriage site, young age, microbial co-carriage with Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis, and recent/concurrent respiratory tract infection were all positively associated with the carriage of M. catarrhalis. Antimicrobial resistance (AMR) testing showed n = 91 (41.4%) of the 220 isolates tested resistant to at least one antibiotic, with the most frequent being resistance to chloramphenicol (n = 76, 34.5%) and ciprofloxacin (n = 64, 29.1%).

  • Open Access

    The Road Less Traveled: Exploring the Genomic Characteristics and Antimicrobial Resistance Potential of Acinetobacter baumannii From the Indigenous Orang Asli Community in Peninsular Malaysia

    by Soo‐Sum Lean, Denise E. Morris, Rebecca Anderson, Ahmed Ghazi Alattraqchi, David W. Cleary, Stuart C. Clarke, Chew Chieng Yeo

    Acinetobacter baumannii is widely recognized as a multidrug‐resistant pathogen, although most public genome datasets are biased toward hospital‐derived isolates. Little is known about A. baumannii isolates from healthy individuals in the community. This study analyzed genome sequences from nine A. baumannii isolates obtained from the upper respiratory tract of the indigenous Orang Asli in their rural community in Peninsular Malaysia. Genomic analysis revealed genetic diversity, including three new Pasteur sequence types (STs) and six novel Oxford STs. One isolate, A. baumannii 19064, belonged to Global Clone 8 (GC8), a lineage linked to clinical infections. Core genome phylogeny showed these community isolates interspersed with clinical isolates from a nearby hospital, indicating potential pathogenicity under suitable conditions. All isolates carried intrinsic bla OXA‐51‐like carbapenemase and bla ADC cephalosporinase genes but remained susceptible to meropenem. Two isolates, A. baumannii 19053 and 19062, were tetracycline resistant but minocycline susceptible, and harbored the tet(39)–tetR gene pair within a mobile p dif module on distinct Rep_3‐type plasmids. Only one isolate, A. baumannii 19055, is plasmid‐free; the rest mainly harbored cryptic plasmids, often containing identifiable p dif modules. These findings highlight the clinical relevance of A. baumannii strains residing in healthy individuals, particularly in isolated communities that are seldom accessible to public health. Despite their remote origins, these isolates possess virulence factors and resistance genes similar to those in hospital settings. This underscores the importance of genomic surveillance of commensal pathogens, as exploring these less‐studied isolates can yield insights into broader epidemiological trends and guide future public health strategies.


  • Open Access

    Carriage epidemiology of Moraxella catarrhalis in an all-age, community cohort between 2016 - 2018

    by Denise E. Morris, Alex J. J. Lister, David W. Cleary, Stuart C. Clarke

    Moraxella catarrhalis is an increasingly important pathogen, recognised as a common cause of respiratory tract infections. It is particularly known for its role in causing otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults. With growing interest in developing vaccines against M. catarrhalis, a deeper understanding of epidemiology in both carriage and disease is crucial. Here we present an all-age, community-based, upper respiratory tract carriage study (the Solent SMART Study) designed to investigate the epidemiology of, and risk factors for M. catarrhalis carriage. In total, n = 1,622 community-based participants were recruited with an additional n = 79 individuals recruited from care/nursing homes in the Southampton/Hampshire UK region from whom a total of n = 228 M. catarrhalis were isolated. Carriage prevalence was 8% (95% CI: 6.7-9.4%) in community-based participants, 19% (95% CI: 11.0-29.4%) in care/nursing home residents and 4.7% (95% CI: 1.6-10.7%) in the community-based subset with COPD (n = 106). Nasopharyngeal carriage site, young age, microbial co-carriage with Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis, and recent/concurrent respiratory tract infection were all positively associated with the carriage of M. catarrhalis. Antimicrobial resistance (AMR) testing showed n = 91 (41.4%) of the 220 isolates tested resistant to at least one antibiotic, with the most frequent being resistance to chloramphenicol (n = 76, 34.5%) and ciprofloxacin (n = 64, 29.1%).

  • Open Access

    Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources

    by Laura C. Zwiers, Diederick E. Grobbee, Rob Schneijdenberg, Corine Baljé, Samantha St. Laurent, Daina B. Esposito, Lei Zhu, Veronica V. Urdaneta, Magalie Emilebacker, Daniel Weibel, et al.

    Background: Myocarditis and pericarditis are recognised risks following COVID-19 vaccination, including the mRNA-1273 vaccine. Most cases occur shortly following the second dose of this vaccine, and incidence is highest among young males. However, little is known about risk factors beyond age and sex and about the longer-term clinical course. This study aims to identify possible risk factors for myocarditis and pericarditis following mRNA-1273 vaccination, to characterise the clinical course of myocarditis and pericarditis, both associated with mRNA-1273 vaccination and not associated with vaccination, and to identify risk factors for severe outcomes (i.e., cardiac or thromboembolic complications, severe hospital outcomes, all-cause hospital readmission, and death). Methods: This study is being conducted within the Vaccine Monitoring Collaboration for Europe (VAC4EU) association using routinely collected healthcare data from five data sources from four European countries (Denmark, Norway, Spain, and the United Kingdom). The study is being performed using a common data model, and all analyses are performed separately in each data source in a federated manner following a common protocol. A case–cohort analysis set is identified within each data source for identifying potential risk factors for myocarditis and pericarditis following mRNA-1273 vaccination using logistic regression analysis. The clinical course of myocarditis and pericarditis is being assessed using a cohort study design and describes all cases (i.e., cases associated with mRNA-1273 and unexposed cases). Cox regression analysis is applied to assess the associations between risk factors and several follow-up outcomes. Conclusions: This protocol describes the study methodology of an international collaborative initiative with the aim of assessing the risk factors and clinical course of myocarditis and pericarditis following mRNA-1273 vaccination using a federated network of five European data sources.

  • Open Access

    The road less travelled: Exploring the genomic characteristics and antimicrobial resistance potential of Acinetobacter baumannii from the indigenous Orang Asli community in Peninsular Malaysia

    by Soo-Sum Lean, Denise E. Morris, Rebecca Anderson, Ahmed Ghazi Alattraqchi, David W. Cleary, Stuart C. Clarke, Chew Chieng Yeo

    Acinetobacter baumannii is widely recognized as a multidrug-resistant pathogen, but with most public genome datasets biased toward hospital-derived isolates. Little is thus known about A. baumannii isolates from healthy individuals from the community. This study analysed genome sequences from nine A. baumannii isolates obtained from the upper respiratory tract of healthy individuals of the indigenous Orang Asli community in their rural settlements located in the east coast of Peninsular Malaysia. Genomic analysis revealed all nine A. baumannii isolates to be genetically distinct and included three new sequence types (STs) under the Pasteur scheme and six novel STs under the Oxford scheme. Notably, one isolate, A. baumannii 19064, belonged to Global Clone 8 (GC8), a lineage associated with clinical infections. Core genome phylogeny indicated that the Orang Asli community isolates were interleaved with several non-GC clinical isolates from the tertiary hospital within the same state. This is suggestive of the potential of these community isolates to cause infections under conducive conditions. This is also attested by the identification of several virulence factors in their genomes. All nine isolates carried various intrinsic bla OXA-51-like class D β-lactamase genes and class C Acinetobacter -derived cephalosporinase (ADC) bla ADC genes but remained susceptible to meropenem. Two isolates, A. baumannii 19053 and 19062, were tetracycline resistant but minocycline susceptible and harboured the tet(39)-tetR gene pair within mobile p dif modules located on distinct Rep_3 family plasmids. Only one isolate, A. baumannii 19055, is plasmid-free; the rest mainly harboured cryptic Rep_3-type plasmids, often containing identifiable p dif modules. These findings highlight the clinical relevance of A. baumannii strains residing in healthy individuals, particularly in isolated communities that are seldom accessible to public health. Despite their remote location, the Orang Asli A. baumannii isolates possess virulence factors and antibiotic resistance genes similar to those found in hospital settings. This underscores the importance of genomic surveillance of commensal pathogens, and taking this road which is less travelled can help inform broader epidemiological insights and guide future public health strategies.

  • Open Access

    The characterization of Moraxella catarrhalis carried in the general population

    by Denise E. Morris, Karen L. Osman, David W. Cleary, Stuart C. Clarke

    Moraxella catarrhalis is a common cause of respiratory tract infection, particularly otitis media in children, whilst it is also associated with the onset of exacerbation in chronic obstructive pulmonary disease in adults. Despite the need for an efficacious vaccine against M. catarrhalis , no candidates have progressed to clinical trial. This study, therefore, aimed to characterize the diversity of M. catarrhalis isolated from the upper respiratory tract of healthy children and adults, to gain a better understanding of the epidemiology of M. catarrhalis and the distribution of genes associated with virulence factors, to aid vaccine efforts. Isolates were sequenced and the presence of target genes reported. Contrary to prevailing data, this study found that lipooligosaccharide (LOS) B serotypes are not exclusively associated with 16S type 1. In addition, a particularly low prevalence of LOS B and high prevalence of LOS C serotypes was observed. M. catarrhalis isolates showed low prevalence of antimicrobial resistance and a high gene prevalence for a number of the target genes investigated: ompB2 (also known as copB), ompCD, ompE, ompG1a, ompG1b, mid (also known as hag), mcaP, m35, tbpA, lbpA, tbpB, lbpB, msp22, msp75 and msp78, afeA, pilA, pilQ, pilT, mod, oppA, sbp2, mcmA and mclS.